| ¿µ¹® | ovarian cancer | ÇÑ±Û | ³¼Ò¾Ï |
|---|---|---|---|
| ¼³¸í | ¿©¼ºÀÇ ³¼Ò¿¡ ¹ß»ýÇÏ´Â ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼ 50¼¼ ÀÌ»ó ¿©¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù. ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀÎ ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î ÀÌ¹Ì ´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼´Â ÈÇпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | cancer | ÇÑ±Û | ¾Ï |
|---|---|---|---|
| ¼³¸í | ³¡¾øÀÌ ºÐ¿À» ÇÏ¿© Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇÏ¿© ´Ù¸¥ Àå±â¿¡±îÁö ÀüÆÄµÉ ¼ö ÀÖ´Â ¼¼Æ÷ÀÇ µ¢¾î¸®. Áï ¾Ç¼º ½Å»ý¹°À» ¸»ÇÑ´Ù. ½Å»ý¹°Àº ¾Ç¼º°ú ¾ç¼ºÀÌ Àִµ¥, ¾Ç¼ºÀÏ °æ¿ì¿¡´Â ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇØ¼ ¸Ö¸® ´Ù¸¥ ¶³¾îÁø Àå±â·Î ¾Ï¼¼Æ÷ÀÇ ÀüÆÄ°¡ °¡´ÉÇÏ¿© ´Ù¸¥ Àå±â¿¡µµ ¾ÏÀ» ÀüÀÌÇϸç, ¾ç¼ºÀº õõÈ÷ ÀÚ¶ó°í ´Ù¸¥°÷À¸·Î ÀüÀ̰¡ »ý±âÁö ¾Ê´Â´Ù. ¾ÏÀº ¾ÏÁ¾°ú À°Á¾ÀÇ µÎ °¡Áö·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º½Å»ý¹°À» À̸£´Â ¸»À̰í À°Á¾À̶õ ºñ»óÇǼº¼¼Æ÷ ƯÈ÷ Áß°£¿±¼¼Æ÷(¹ß»ý´ç½Ã¿¡ Áß°£¿±¿¡ ÇØ´çÇÏ´Â Á¶Á÷À¸·Î ¹ß»ýÈÄ¿¡ Á¶Á÷»çÀÌ¿¡ ºÐÆ÷ÇÏ¸é¼ Á¶Á÷À» ÁöÁöÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °áÇÕÁ¶Á÷, Ç÷°ü, ¸²ÇÁ°ü µîÀÌ µÈ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º ½Å»ý¹°À» À̸£´Â ¸»ÀÌ´Ù. |
||
| ¿µ¹® | cancer surgery | ÇÑ±Û | ¾Ï ¼ö¼ú |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ 4´ë Ä¡·á¹ýÀº ¿Ü°úÀû ¼ö¼ú¿ä¹ý, ¹æ»ç¼± Ä¡·á¹ý, Ç×¾Ï ÈÇпä¹ý, ¸é¿ª¿ä¹ý µîÀ» ¸»Çϸç ÀÌÁß ¼ö¼ú¿ä¹ý°ú ¹æ»ç¼± ¿ä¹ýÀº ±¹¼ÒÀû ¿ä¹ýÀ¸·Î¼ ¾Ï¼¼Æ÷°¡ ¿ø¹ßÀå±â(óÀ½ ¾ÏÀÌ ¹ß»ýÇÑ Àå±â)³ª ±¹¼Ò ¸²ÇÁÀý±îÁö ±¹ÇѵǾî ÀÖ´Â Á¦ 1, 2±â ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. ÈÇпä¹ý°ú ¸é¿ª¿ä¹ýÀº Àü½Å¿ä¹ýÀ¸·Î¼ Á¦ 3, 4±â ¾Ï¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, 1, 2±â ¾ÏÀÇ Ä¡·á ÈÄ ´«¿¡ º¸ÀÌÁö ¾Ê°Ô ³²¾Æ ÀÖÀ» ¼ö ÀÖ´Â ÀÜ·ù¾Ï¼¼Æ÷³ª ¹Ì¼¼ÀüÀÌ ¾Ï¼¼Æ÷ÀÇ ¿ÏÀüÆÄ±«, »ç¸êÀ» À§ÇØ »ç¿ëµÈ´Ù. ¹éÇ÷º´, ¸²ÇÁÁ¾°ú °°ÀÌ ÈÇпä¹ýÁ¦¿¡ Àß µè´Â Ç÷¾×¾Ï, ¸²ÇÁÁ¾°ú °íȯÁ¾°ú °°ÀÌ ¹æ»ç¼± Ä¡·á¿¡ Àß µè´Â ¾ÏÀ» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ °íÇü¾Ï(solid tumor)ÀÎ À§Ã¢ÀÚ°ü¾Ï, °£¾Ï, ÀÌÀÚ¾Ï, À¯¹æ¾Ï, °©»ó»ù¾Ï, Æó¾Ï, Èæ»öÁ¾, ¿¬Á¶Á÷¾Ï, »ÀÀ°Á¾, ħ»ù¾Ï µîÀº ¸ðµÎ ¼ö¼ú¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¾Ï¼ö¼úÀÇ ±âº»¿øÄ¢: ¾Ï¼ö¼úÀÇ 3°¡Áö ±âº»¿ä°ÇÀº ¾ÈÀü¼º, ±ÙÄ¡¼º, ±â´Éº¸Á¸¼ºÀÌ¸ç ¾Ï¼ö¼ú½Ã¿¡´Â ¾Ïº´Å͸¦ µÇµµ·Ï Á¶½ÉÇØ¼ Àû°Ô ¸¸Áö¸é¼ ¼ö¼úÇÏ°í ¾Ïº´Å͸¦ °ø±ÞÇÏ´Â µ¿Á¤¸Æ°ú ¸²ÇÁ°üÀ» ¸ÕÀú °áÂûÇÏ¿© ¾Ïº´ÅͰ¡ ÆÛÁö´Â °ÍÀ» ¹æÁöÇÑ´Ù. ¾Ï¼ö¼úÀÇ ¸ñÇ¥´Â ±ÙÄ¡Àû ÀýÁ¦¼ö¼ú(radical surgery)ÀÌ´Ù. ±×·¯³ª À̰ÍÀÌ ºÒ°¡´ÉÇÑ È¯ÀÚ¿¡¼´Â ÃâÇ÷, Æó»ö, õ°ø µîÀÇ ÇÕº´ÁõÀÌ ¹ß»ýÇßÀ»¶§ ±¸±Þ¸ñÀûÀ¸·Î ȤÀº Áö¼ÓÀû µ¿ÅëÀÌ ÀÖÀ»¶§ »ýȰ³»¿ëÀÇ ÁúÀû °³¼±À» À§ÇÏ¿© °í½ÄÀû ¼ö¼ú(palliative surgery)À» ÇÑ´Ù. ±×¸®°í ¾ÏÀÇ Á¤È®ÇÑ Áø´Ü°ú ÁøÇ൵ÀÇ °áÁ¤À» À§ÇÑ Áø´ÜÀû ¼ö¼ú(diagnostic surgery)ÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | breast cancer | ÇÑ±Û | À¯¹æ¾Ï |
|---|---|---|---|
| ¼³¸í | À¯¹æÀº Áö¹æÁ¶Á÷°ú º»·¡ÀÇ ¸ñÀûÀÎ Á£À» »ý»êÇÏ´Â »ùÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷¿¡¼ »ý»êÇÑ Á£À» ¹Û¿¡±îÁö ³»º¸³»´Â °üÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ ÁÖÀ§¸¦ µÑ·¯½Î°í ÀÖÀ¸¸é¼ À̰͵éÀÇ ¸ð¾çÀ» À¯ÁöÇØÁÖ´Â °£Áú·Î ÀÌ·ç¾îÁø´Ù. À¯¹æ¾ÏÀ̶õ »ùÁ¶Á÷°ú °üÁ¶Á÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀ» ¸»ÇÑ´Ù. À¯¹æ¾ÏÀ» ¹ß»ý½Ãų ¼ö ÀÖ´Â À§ÇèÀÎÀÚ´Â ¿©·¯ °¡Áö°¡ ¹àÇôÁ® ÀÖ´Ù. ±×Áß¿¡¼ ´ëÇ¥ÀûÀÎ °ÍÀº ´ÙÀ½°ú °°´Ù. 1.À¯ÀüÀû ¿äÀΣ°¡Á· Áß¿¡¼ À¯¹æ¾Ï¿¡ °É¸° »ç¶÷ÀÌ ÀÖÀ¸¸é À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀÌ ¾ÆÁÖ ³ô¾ÆÁø´Ù. 2.¿¡½ºÆ®·Î°Õ¿¡ Àå±âÀûÀ¸·Î ¸¹ÀÌ Æø·ÎµÇ´Â °æ¿ì£¿¡½ºÆ®·Î°ÕÀº ¿©¼ºÈ£¸£¸óÀ¸·Î ¿©¼º¿¡¼ Á¤»óÀûÀ¸·Î »ý¸®ÀÇ Áֱ⿡ µû¶ó Áõ°¨À» µÇÇ®ÀÌÇÑ´Ù. ÀÌ ¿¡½ºÆ®·Î°ÕÀº À¯¹æÀÇ Á¥»ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ Áõ½Ä°ú ¼ºÀå¿¡ °ü°èÇÑ´Ù. ±×¸®°í ÀÌ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·ÎµÇ´Â »ç¶÷Àº À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. ¿ÜºÎ¿¡¼ ¿¡½ºÆ®·Î°ÕÀÇ Á¦Á¦¸¦ Ä¡·á¸ñÀûÀ¸·Î Åõ¿©ÇÒ °æ¿ì¿¡ À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀº Á¤»óÀο¡¼ º¸´Ù ÇöÀúÇÏ°Ô ³ô¾ÆÁø´Ù. ±×¸®°í ¾ÆÀ̸¦ ³ºÁö ¾Ê°í Æò»ýÀ» »ç´Â ¿©ÀÚÀÇ °æ¿ì¿¡ ÀÓ½ÅÀ» ÇÏ°í ¾ÆÀ̸¦ ³ºÀº ¿©ÀÚ¿¡ ºñÇØ¼ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·Î°¡ µÇ¹Ç·Î(ÀӽŽÿ¡´Â ºñÀӽŽú¸´Ù ¿¡½ºÆ®·Î°Õ¿¡ Àû°Ô Æø·Î°¡ µÈ´Ù)À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. 3.ȯ°æÀû ¿äÀΣÁö¹æÁú ¼·ÃëÀÇ Áõ°¡, ¼úÀÇ ¼·Ãë µîÀº À¯¹æ¾ÏÀÇ È®·üÀ» ³ôÀδÙ. À¯¹æ¾ÏÀÇ Áõ»óÀ¸·Î °¡Àå ¸¹Àº °ÍÀº ¾ÆÇÁÁö ¾ÊÀº À¯¹æÀÇ µ¢¾î¸®ÀÌ´Ù. ±×¸®°í À¯µÎ¿¡¼ ºÐºñ¹°ÀÌ ³ª¿À°Å³ª, À¯¹æÀÇ ÇǺκ¯È µîÀÌ À¯¹æ¾ÏÀÇ ÈçÇÑ Áõ»óÀÌ´Ù. Ä¡·á´Â À¯¹æÀÇ ÀýÁ¦¼úÀÌ °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î µÇ¾îÀÖ´Ù. ±×¸®°í À̰Ϳ¡ ´õÇÏ¿© ¹æ»ç¼± Ä¡·á³ª Ç×¾ÏÁ¦¿ä¹ýµµ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î µÇ¾îÀÖ´Ù. ¶Ç ¿¡½ºÆ®·Î°ÕÀÇ °úÀ×°ú °ü°è°¡ ÀÖ´Â Á¾¾çÀÏ °æ¿ì¿¡´Â ¿¡½ºÆ®·Î°ÕÀÇ È¿°ú¸¦ Â÷´ÜÇÏ´Â ¾à¹°µµ È¿°ú°¡ ÀÖ´Ù. |
||
| ¿µ¹® | cervix cancer | ÇÑ±Û | Àڱøñ¾Ï, ÀڱðæºÎ¾Ï |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼ ¹ß»ýÇÏ´Â ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷´Â óÀ½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇÏ¸é »óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ ÀÖ´Â ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î ħÀ±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ ä¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ ä¿ö¹ö·Á Á¤»óÀûÀÎ ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î ħ¹üÇØ ³ª°¡´Â °æ¿ì¸¦ ħÀ±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í ù ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù. Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È¸¦ °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î äÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù. Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý ħÀ±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇÏ´Â °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀÇ Ä§À±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù. |
||
| CC | calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card... |
|---|---|
| AIDSDRUGS | clinical trials of acquired immunodeficiency drugs [MEDLARS data base] |
| AIDSTRIALS | clinical trials of acquired immunodeficiency syndrome drugs [MEDLARS data base] |
| CTN | calcitonin; clinical trials notification; computer tomography number; continuous noise |
| CTS | carpal tunnel syndrome; clinical trials support [program]; composite treatment score; computed tomog... |
| ACTG | AIDS Clinical Trials Group |
|---|---|
| CCTs | Controlled clinical trials |
| PACTG | Paediatric AIDS Clinical Trials Group |
| RCT | Randomized controlled clinical trials |
| ASCO | American Society of Clinical Oncology |
| clinical research trials | Evaluating the safety and effectiveness of medications or medical devices by monitoring their effects on large groups of people. Clinical medical trials sponsored by the U. S. Government are listed on a web site of the National Institutes of Health (NIH). The NIH Clinical Centre intends to make details of current clinical research studies for various diseases available over the Internet to increase opportunities for patients and physicians to participate in clinical investigations. (12 Dec 1998) |
|---|---|
| clinical trials | Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer. (12 Dec 1998) |
| clinical trials, phase I | Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries. (12 Dec 1998) |
| clinical trials, phase II | Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries. (12 Dec 1998) |
| clinical trials, phase III | Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries. (12 Dec 1998) |
| clinical trials, phase IV | Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries. (12 Dec 1998) |
| controlled clinical trials | Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials. (12 Dec 1998) |
| randomised controlled trials | Clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and trials employing any of these techniques for patient assignment are designated simply controlled clinical trials. (12 Dec 1998) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|